Merck & Co., Inc.
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All MRK news ›Merck & Company (MRK) Receives a Buy from UBS
UBS analyst Michael Yee maintained a Buy rating on Merck & Company today and set a price target of $175.00. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb. According to…
Merck & Company (MRK) Gets a Buy from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley assigned a Buy rating to Merck & Company, with a price target of $179.00. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Merck & Company, and Amgen.…
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
A protein-vaccine developer with no fresh catalyst just posted a double-digit gain that dwarfs what Moderna and Merck managed in the same session, and the explanation reveals something uncomfortable about how this stock actually moves.…
Does The Move In Merck Stock Change Anything?
Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a year of drug approvals and clinical trial results, arriving just as the company prepares for the patent loss on…
A day in the life of a Merck R&D chief
Dr. Eliav Barr pulls back the curtain on what it’s like to manage Merck’s fast-growing pipeline. Welcome to “Day in the Life,” a series examining what it’s like to walk in a pharma exec’s shoes. Today, we’re going behind the scenes with…
Our Beloved Merck
It started when I was in college. I was pursuing degrees in journalism and broadcasting. It occurred to me that if I could work part-time jobs in those fields, then once I graduated from college, I would be ahead of others. This was a new…
Tempus AI Expands Collaboration with Merck and Moderna on Individualized Neoantigen Therapy
Eric Lefkofsky, Founder and CEO of Tempus, shared Tempus AI’s post on LinkedIn, adding: “Sequencing is no longer just about matching a patient to an existing treatment – with individualized therapies, it’s becoming an integral part of the…
Merck gets cancer drug bar as Halozyme wins cross-border European injunction | MLex | Specialist news and analysis on legal risk and regulation
Merck gets cancer drug bar as Halozyme wins cross-border European injunction MLex Merck gets cancer drug bar as Halozyme wins cross-border European injunction Prepare for tomorrow’s regulatory change, today MLex identifies risk to business…
HP, Merck, and Seagate Just Paid Their Shareholders. Here’s What Landed in Their Accounts.
On October 7, three companies with nothing in common sent cash to their shareholders, but the differences in what each paid, how fast each raised it, and what the stock price does to the math tell three very different income… Merck is a…
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO
Timmerman Report You may also like Get In-depth Biotech Coverage with Timmerman Report. What Readers Are Saying
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com59
-
investments.halifax.co.uk30
-
finance.yahoo.com22
-
moneymorning.com21
-
seekingalpha.com16
Measured across the 4Comedy news index. Headline tone is a simple word-based reading of the latest 120 headlines, not a forecast.